{"count": 13, "results": [{"_id": "34195068", "pmid": 34195068, "pmcid": "PMC8236717", "title": "Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma", "journal": "Front Oncol", "authors": ["Jiang XN", "Zhang Y", "Wang WG", "Sheng D", "Zhou XY", "Li XQ"], "date": "2021-06-14T00:00:00Z", "doi": "10.3389/fonc.2021.608238", "meta_date_publication": "2021", "meta_volume": "11", "meta_issue": "", "meta_pages": "608238", "score": 50288.59, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ inhibits the growth rates of three @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@DLBCL@@@ cell lines (A). ", "citations": {"NLM": "Jiang XN, Zhang Y, Wang WG, Sheng D, Zhou XY, Li XQ. Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma Front Oncol. 2021;11():608238. PMID: 34195068", "BibTeX": "@article{34195068, title={Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma}, author={Jiang XN and Zhang Y and Wang WG and Sheng D and Zhou XY and Li XQ}, journal={Front Oncol}, volume={11}, pages={608238}}"}}, {"_id": "35860311", "pmid": 35860311, "pmcid": "PMC9289755", "title": "Influence of Hyperglycemia on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma", "journal": "Diabetes Metab Syndr Obes", "authors": ["Zhou W", "Li W", "He C", "Ma R", "Gao Q", "Wang Y", "Feng L", "Liu L"], "date": "2022-07-13T00:00:00Z", "doi": "10.2147/DMSO.S370017", "meta_date_publication": "2022", "meta_volume": "15", "meta_issue": "", "meta_pages": "2039-2049", "score": 50280.4, "text_hl": "To explore the effects of primary and secondary @DISEASE_Hyperglycemia @DISEASE_MESH:D006943 @@@hyperglycemia@@@ and the application of the hypoglycemic drug @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on the prognosis of @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@diffuse large B-cell lymphoma@@@ (@<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@DLBCL@@@).", "citations": {"NLM": "Zhou W, Li W, He C, Ma R, Gao Q, Wang Y, Feng L, Liu L. Influence of Hyperglycemia on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma Diabetes Metab Syndr Obes. 2022;15():2039-2049. PMID: 35860311", "BibTeX": "@article{35860311, title={Influence of Hyperglycemia on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma}, author={Zhou W and Li W and He C and Ma R and Gao Q and Wang Y and Feng L and Liu L}, journal={Diabetes Metab Syndr Obes}, volume={15}, pages={2039-2049}}"}}, {"_id": "32647571", "pmid": 32647571, "pmcid": "PMC7336499", "title": "Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma", "journal": "Cancer Metab", "authors": ["Singh AR", "Gu JJ", "Zhang Q", "Torka P", "Sundaram S", "Mavis C", "Hernandez-Ilizaliturri FJ"], "date": "2020-07-06T00:00:00Z", "doi": "10.1186/s40170-020-00213-w", "meta_date_publication": "2020", "meta_volume": "8", "meta_issue": "", "meta_pages": "10", "score": 50277.17, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ sensitizes therapeutic agents and improves outcome in pre-clinical and clinical @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@diffuse large B-cell lymphoma@@@", "citations": {"NLM": "Singh AR, Gu JJ, Zhang Q, Torka P, Sundaram S, Mavis C, Hernandez-Ilizaliturri FJ. Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma Cancer Metab. 2020;8():10. PMID: 32647571", "BibTeX": "@article{32647571, title={Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma}, author={Singh AR and Gu JJ and Zhang Q and Torka P and Sundaram S and Mavis C and Hernandez-Ilizaliturri FJ}, journal={Cancer Metab}, volume={8}, pages={10}}"}}, {"_id": "39479950", "pmid": 39479950, "title": "Single and Combinatorial Effects of Metformin and Thymoquinone in Diffuse Large B Cell Lymphoma Cells.", "journal": "Chem Biodivers", "authors": ["Glamočlija U", "Mahmutovic L", "Bilajac E", "Šoljić V", "Vukojević K", "Sezer A", "Suljagić M"], "date": "2024-10-31T00:00:00Z", "doi": "10.1002/cbdv.202401533", "meta_date_publication": "2024 Oct 31", "meta_volume": "", "meta_issue": "", "meta_pages": "e202401533", "score": 50262.727, "text_hl": "Single and Combinatorial Effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @CHEMICAL_thymoquinone @CHEMICAL_MESH:C003466 @@@Thymoquinone@@@ in @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@Diffuse Large B Cell Lymphoma@@@ Cells.", "citations": {"NLM": "Glamočlija U, Mahmutovic L, Bilajac E, Šoljić V, Vukojević K, Sezer A, Suljagić M. Single and Combinatorial Effects of Metformin and Thymoquinone in Diffuse Large B Cell Lymphoma Cells. Chem Biodivers. 2024 Oct 31;():e202401533. PMID: 39479950", "BibTeX": "@article{39479950, title={Single and Combinatorial Effects of Metformin and Thymoquinone in Diffuse Large B Cell Lymphoma Cells.}, author={Glamočlija U and Mahmutovic L and Bilajac E and Šoljić V and Vukojević K and Sezer A and Suljagić M}, journal={Chem Biodivers}, pages={e202401533}}"}}, {"_id": "39941763", "pmid": 39941763, "title": "Metabolic Heterogeneity in Diffuse Large B-Cell Lymphoma Cells Reveals an Innovative Antimetabolic Combination Strategy.", "journal": "Cancers (Basel)", "authors": ["Lordello L", "Nuan-Aliman S", "Kielbassa-Elkadi K", "Montagne A", "Kotta K", "Martins I", "Pinto Jurado E", "Caradeuc C", "Lehmann-Che J", "Martínez-Climent JÁ", "Meignin V", "Giraud N", "Kroemer G", "Bertho G", "Thieblemont C", "Baud V"], "date": "2025-01-24T00:00:00Z", "doi": "10.3390/cancers17030394", "meta_date_publication": "2025 Jan 24", "meta_volume": "17", "meta_issue": "3", "meta_pages": "", "score": 50258.58, "text_hl": "Methods: We investigated the effects of combining @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ and L-asparaginase, two FDA-approved antimetabolic drugs, on @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@DLBCL@@@ cell metabolism and survival. ", "citations": {"NLM": "Lordello L, Nuan-Aliman S, Kielbassa-Elkadi K, Montagne A, Kotta K, Martins I, Pinto Jurado E, Caradeuc C, Lehmann-Che J, Martínez-Climent JÁ, Meignin V, Giraud N, Kroemer G, Bertho G, Thieblemont C, Baud V. Metabolic Heterogeneity in Diffuse Large B-Cell Lymphoma Cells Reveals an Innovative Antimetabolic Combination Strategy. Cancers (Basel). 2025 Jan 24;17(3):. PMID: 39941763", "BibTeX": "@article{39941763, title={Metabolic Heterogeneity in Diffuse Large B-Cell Lymphoma Cells Reveals an Innovative Antimetabolic Combination Strategy.}, author={Lordello L and Nuan-Aliman S and Kielbassa-Elkadi K and Montagne A and Kotta K and Martins I and Pinto Jurado E and Caradeuc C and Lehmann-Che J and Martínez-Climent JÁ and Meignin V and Giraud N and Kroemer G and Bertho G and Thieblemont C and Baud V}, journal={Cancers (Basel)}, volume={17}, number={3}}"}}, {"_id": "36276140", "pmid": 36276140, "pmcid": "PMC9583025", "title": "Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma", "journal": "Front Oncol", "authors": ["Liu MK", "Cheng LL", "Yi HM", "He Y", "Li X", "Fu D", "Dai YT", "Fang H", "Cheng S", "Xu PP", "Qian Y", "Feng Y", "Liu Q", "Wang L", "Zhao WL"], "date": "2022-10-06T00:00:00Z", "doi": "10.3389/fonc.2022.885011", "meta_date_publication": "2022", "meta_volume": "12", "meta_issue": "", "meta_pages": "885011", "score": 50250.793, "text_hl": "The addition of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ significantly decreased the M2 proportion and the CD36 expression level in the coculture systems, indicating that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ could target altered @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@ metabolism and decrease M2 macrophages in @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@DLBCL@@@, especially in @GENE_CD5 @GENE_921 @@@CD5@@@+ non-DE @DISEASE_Lymphoma @DISEASE_MESH:D008223 @@@lymphoma@@@. ", "citations": {"NLM": "Liu MK, Cheng LL, Yi HM, He Y, Li X, Fu D, Dai YT, Fang H, Cheng S, Xu PP, Qian Y, Feng Y, Liu Q, Wang L, Zhao WL. Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma Front Oncol. 2022;12():885011. PMID: 36276140", "BibTeX": "@article{36276140, title={Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma}, author={Liu MK and Cheng LL and Yi HM and He Y and Li X and Fu D and Dai YT and Fang H and Cheng S and Xu PP and Qian Y and Feng Y and Liu Q and Wang L and Zhao WL}, journal={Front Oncol}, volume={12}, pages={885011}}"}}, {"_id": "35304777", "pmid": 35304777, "title": "Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma.", "journal": "Hematol Oncol", "authors": ["Li X", "Liu M", "Shi Q", "Fang Y", "Fu D", "Shen ZX", "Yi H", "Wang L", "Zhao W"], "date": "2022-03-18T00:00:00Z", "doi": "10.1002/hon.2993", "meta_date_publication": "2022 Mar 18", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50248.402, "text_hl": "Taken together, pretreatment serum @GENE_IL13 @GENE_3596 @@@IL-13@@@ level is related to the immunosuppressive microenvironment and poor clinical outcome of @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@DLBCL@@@ @SPECIES_9606 @@@patients@@@ and could be targeted by @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, thus providing a new therapeutic strategy in treating @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@DLBCL@@@ with high serum @GENE_IL13 @GENE_3596 @@@IL-13@@@ levels.", "citations": {"NLM": "Li X, Liu M, Shi Q, Fang Y, Fu D, Shen ZX, Yi H, Wang L, Zhao W. Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma. Hematol Oncol. 2022 Mar 18;():. PMID: 35304777", "BibTeX": "@article{35304777, title={Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma.}, author={Li X and Liu M and Shi Q and Fang Y and Fu D and Shen ZX and Yi H and Wang L and Zhao W}, journal={Hematol Oncol}}"}}, {"_id": "35203557", "pmid": 35203557, "pmcid": "PMC8961793", "title": "The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells", "journal": "Biomedicines", "authors": ["Nuan-Aliman S", "Bordereaux D", "Thieblemont C", "Baud V"], "date": "2022-02-01T00:00:00Z", "doi": "10.3390/biomedicines10020348", "meta_date_publication": "2022 Feb 1", "meta_volume": "10", "meta_issue": "2", "meta_pages": "", "score": 50246.914, "text_hl": "Therefore, we evaluated the impact of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ on @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@DLBCL@@@ cell survival upon @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ deprivation. ", "citations": {"NLM": "Nuan-Aliman S, Bordereaux D, Thieblemont C, Baud V. The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells Biomedicines. 2022 Feb 1;10(2):. PMID: 35203557", "BibTeX": "@article{35203557, title={The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells}, author={Nuan-Aliman S and Bordereaux D and Thieblemont C and Baud V}, journal={Biomedicines}, volume={10}, number={2}}"}}, {"_id": "37738652", "pmid": 37738652, "title": "EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B cell lymphoma.", "journal": "Blood", "authors": ["Liu Y", "Kimpara S", "Hoang NM", "Daenthanasanmak A", "Li Y", "Lu L", "Ngo VN", "Bates P", "Song L", "Gao X", "Bebel S", "Chen M", "Chen R", "Zhang X", "Selberg PE", "Kenkre VP", "Capitini CM", "Waldmann T", "Rui L"], "date": "2023-09-22T00:00:00Z", "doi": "10.1182/blood.2023020142", "meta_date_publication": "2023 Sep 22", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50246.785, "text_hl": "These findings suggest that targeting @GENE_EGR1 @GENE_1958 @@@EGR1@@@-mediated metabolic reprogramming to OXPHOS with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ or IM156 provides a potential therapeutic strategy to overcome @CHEMICAL_ibrutinib @CHEMICAL_MESH:C551803 @@@ibrutinib@@@ resistance in relapsed/refractory @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@DLBCL@@@ or @DISEASE_Lymphoma_Mantle_Cell @DISEASE_MESH:D020522 @@@MCL@@@.", "citations": {"NLM": "Liu Y, Kimpara S, Hoang NM, Daenthanasanmak A, Li Y, Lu L, Ngo VN, Bates P, Song L, Gao X, Bebel S, Chen M, Chen R, Zhang X, Selberg PE, Kenkre VP, Capitini CM, Waldmann T, Rui L. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B cell lymphoma. Blood. 2023 Sep 22;():. PMID: 37738652", "BibTeX": "@article{37738652, title={EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B cell lymphoma.}, author={Liu Y and Kimpara S and Hoang NM and Daenthanasanmak A and Li Y and Lu L and Ngo VN and Bates P and Song L and Gao X and Bebel S and Chen M and Chen R and Zhang X and Selberg PE and Kenkre VP and Capitini CM and Waldmann T and Rui L}, journal={Blood}}"}}, {"_id": "35181615", "pmid": 35181615, "title": "Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications.", "journal": "Ann Clin Lab Sci", "authors": ["Brown RE", "Zhang S", "Wang XI"], "date": "2022-01-01T00:00:00Z", "meta_date_publication": "2022 Jan", "meta_volume": "52", "meta_issue": "1", "meta_pages": "27-32", "score": 50245.293, "text_hl": "Similarly, the fact that @GENE_EZH2 @GENE_2146 @@@EZH2@@@ can enhance the expression of @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumoral@@@ stem cell marker, @GENE_CXCR4 @GENE_7852 @@@CXCR4@@@ implies that there is a block in differentiation in @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@DLBCL@@@. CONCLUSION: By targeting the @GENE_SIRT1 @GENE_23411 @@@Sirt1@@@, @GENE_EZH2 @GENE_2146 @@@EZH2@@@ and @GENE_CXCR4 @GENE_7852 @@@CXCR4@@@ pathways using relatively non-toxic adjuvant therapeutic agents such as @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, @CHEMICAL_Melatonin @CHEMICAL_MESH:D008550 @@@melatonin@@@, @CHEMICAL_Curcumin @CHEMICAL_MESH:D003474 @@@curcumin@@@, @CHEMICAL_sulforaphane @CHEMICAL_MESH:C016766 @@@sulforaphane@@@, @CHEMICAL_Cholecalciferol @CHEMICAL_MESH:D002762 @@@vitamin D3@@@ and @CHEMICAL_plerixafor @CHEMICAL_MESH:C088327 @@@plerixafor@@@, we should be able to target the biology of @<m>DISEASE_Lymphoma_Large_B_Cell_Diffuse</m> @DISEASE_MESH:D016403 @@@DLBCL@@@.", "citations": {"NLM": "Brown RE, Zhang S, Wang XI. Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications. Ann Clin Lab Sci. 2022 Jan;52(1):27-32. PMID: 35181615", "BibTeX": "@article{35181615, title={Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications.}, author={Brown RE and Zhang S and Wang XI}, journal={Ann Clin Lab Sci}, volume={52}, number={1}, pages={27-32}}"}}]}